Clinical trial
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2009-2010, When Administered to Elderly Subjects
NCT00956761 is registered in ClinicalTrials.gov with Novartis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2009-2010, When Administered to Elderly Subjects
- Lead sponsor
- Novartis
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2009
- Completion date
- June 30, 2009
- Enrollment
- 63 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
seasonal influenza